|Title of Invention||
AN AYURVEDIC MEDICINE FOR CURING VIRAL HEPATITIS AND THE LIKE DISEASES.
|Abstract||ABSTRACT OF THE INVENTION An ayurvdic medicine / formulation for curing viral hepatatis /jaundice, australia antigen, chronic hisnophilic cold and the like diseases by flushing out of the body excess biluribum and virus comprising extract of dry fibrous fruit of Luffa Aegyptiaca / Luffa Aegyptica / Luffa Cylindrica or Aluffa Acutangula or Luffa Operculata and seeds of Cuminum Cyminum, human breast milk / animal milk / water forming a homogeneous solution.|
This invention relates to an Ayurvedic Medicine for curing Viral Hepatitis of the types A, C. D„ E and Hepatitis B and the like diseases.
Invention also releates to preparation formulations and adminstration of ayurvedic medicine for curing viral hepatatis of types A, C, D, E and Hepatatis B.
More particularly this invention relates to an Ayurvedic Medicine / formulations to be used in the form of Nasal Drops for flushing our the excess bilirubin and bad germs and viruses out of the human body and curing viral hepatitis / Jaundice.
Viral diseases have been very difficult to cure in general and has toubled the mankind since times immemorial. Een very minor diseases like common cold does not have a sure cure as the virus changes its structure to survive in the body. Viral Hepatitis (Jaundice) is one of the viral diseases which does not have any cure or medical remedy till to date in Allopathic medicine inspite of years of research because the medical science did not find out the virus which caused viral hepatitis. A sure cure for this in other forms of medicine is also not existing and if it exists the public is not aware of it. Ayurveda has various medicines for jaundice. Some of the common ayrvedic medicines are KEEZHARNELLI, LEAVES OF VEP TREE, tender leaves of CASTOR PLANT and the like. Some drugs based on these are also available in the market like the Liv =52 tablets and Livosin tonic nm\ the like and are generally the medicines prescribed by the doctors since no cure exists for jaundice. Although these drugs improved the liver condition but none of them have been acting as a cure for jaundice / Viral Hepatitis. Some physician give these medicines to jaundice/Viral Hepatitis patients of types A and E and have been able to cure them if the disease is in early/beginning stages. The physicians are strictly controlling the patients diet such as avoiding salt/oil and some type of vegetables also.
The various types of Hepatitis A,B,C,D,E / Jaundice out of which (C and E are not common in India) and have further complicated varieties including Australia antigen and the like. Many Viral Hepatitis / Jaundice patients get cured by themselves when by taking rest, the body builds up the inbuilt defence mechanism to resist the vims in initial stages. Seemingly, all that an allopathic doctor can prescribe to a jaundice patient is to admit him in the hospital, put him on a saline glucose drip, full rest and give himsome drugs such as Liv 52 and the like and generally as mentioned before the patient survives if the disease is in tis early stages. But in chronic cases or acute cases where the bilirubin content of the blood does not come to normal and instead keeps increasing, the patients die either due to the jaundice turning to cirrhosis / liver cance or when the bilirubin level rises above what the patients body can take. All such patients reach this severe stage sice there is no medicine in the world to flushc out the excess bilirubin and vims in the patients's body and check its level from rising. Thus, thousands of people die of jaundince even today some not enven aware of the diseaase which killed them.
A healthy person has a normal bilirubin content of about .2 mg direct and 0.9 mg indirect. In his blood and when infected by jaundince this level keeps rising ans the disease gets chronic. Very few patients cross the level of 20 and above and recuperate. Almost all of them die sooner or later. Vaccines exist for viral hepatitis which improves the immunity of the person against the disease. Various typs and kinds of plasma based and other vaccines are avilable in the market today. But it is pertinent to mention that tyhey are not 100% successful in providing immunity against the disease. However, the fact remains that if the person gets Viral Hepatitis / Jaundice then there is no cure for it other than to hope that by taking rest, the body will repair the damage on tis won. There areotehr cases where the body gets jaundice due to side effects of strong drugs taken against some other disease or in some leukeamia patients after the bone marrow transplant due to graft v/s host disease. These are not virally infected but the symptoms and problems of curing arwe the same like any other jaundice and in many cases further medication for the main disease is not possible due to this jaundice complication and the high bilirubin count. NO ALLOPATHIC MEDICINE TODAY IN THE WORLD for flushing out the excess bilirubin and vims out of the human body and curing viral hepatitis.
Main object of this invention is to provide an Ayurvedic Medicine / formulation which is able to cure all the types of Hepatitis, severity and complications including Viral Hepatitis / Jaundice and Australia Antigen and its associated complications like severe itching all over the body.
Another object of this invention is to provide and Ayurvedic Medicine / Formulation, which is capable of flushing out the excess bilirubin and vims out of the human body.
A further object of this invention is to provide an Ayurvedic Medicine / Formulation, which is capable of curing chronic hisnophilic cold, characterised by heavy and frequent sneezing, cold and wheezing.
A further object of this invention is to provide and Ayurvedic medicine/ Formulation, which does not have any side effects or adverse effects or nullifying effects of any other drugs, or no other durg has any nullifying effect to this medicine and hence this medicine can be given to patients who are already under medication for some other ailment alongwilh hepatitis /jaundice.
A further object of this invenin is to provide an Ayurvedic Medicine/ Formulation, which besides curing all types of viral hepatitis/jaundice and the like diseases and flushing the excess bilirubin and vims out of the human body is capable of strong revival in the apitite and regaining the energy in the body, so that the patients are ready for their normal work and life, within no time. The patient can eat all types of food, using salt, oil, fish and all items of vegetable in their disease stage also.
A further object of this invention is to provide an Ayurvedic medicine formulation which is very effective and capable of curing viral hepatitis / jaundice and the like disease by flushing out of the body excess bilirubin and vims thereby bringing down the bilirubin level in blood plasma to a normal level.
FORMULATION OF THE MEDICINE
a) The ingredients of the medicine are as follows:
1. Dry fibrous Fruit of LUFFA AEGYPTIACA/LUFFA AEGYPTICA/LUFFA CYLINDRICA or LUFFA ACUTANGULA or LUFFA OPERCULATA (hence forth known in the document as INGREDIENT-1)
2. Seeds of CUMINUM CYMINUM (hence forth known in th document as INGREDIENT-2)
3. Human brest milk or water-hence forth known in the document as TNGREDIENT-3). The usage of human breast milk is more recommended.
INGREDIENT-1 and INGREDIENT-2 is taken in proportions corresponding to dosage required and these are squeezed into INGREDIENT-3 to obtain extracts of these ingredients to a solution which is administered as nasal drops.
A normal dose consists of 2 gms of Ingredient-1 and 2 gms of Ingredient - 2 in 5 ml of lngredient-3. The strength of the dose is increased by increasing the quantity of Ingredient-1 and 2 in the Ingredient-3. Varying of dosages and its effects are detailed later in the document.
ADMINISTRATION OF THE MEDICINE AND ITS EFFECTS
The medicine prepared into the solution as described above is to be administered as nasal drops to the patient. The volume of medicine to be applied also depends on the severity of the disease and the corresponding Bilirubin cound of the patient. Typically 2ml of the medicine os administered into each nose of an adult patient.
Immediately on administering the medicine, irritation and tendency to sneeze will occcur in the patient as with nasal drops. In addition, a bitter taste is felt at the throat of the patient as the medicinal drops flows through the nasal tract into the throat and then is swallowed by the patient. Within Vi-2 hour of administering the medicine, the patient is advised to take bath in normal water. An hour subsequently the patient may experience throat pain and mucous discharge through nose and mouth. This condition may persist for 24 his generally of yellow colour indicating the release of excess Bilirubin in the body. The throat pain is seen to persist up to 48 hours in very few cases whose throats are very sensitive. The pain increases when the patient tends to sneeze hard and is minimal in case the patient simply absorbs the discharge using a soft cloth as it comes out. The patient is advisesd rest from al heavy physical activities which leads to heating of the body and also advised bathing twice daily, preferably once in the morning and once in the evening to cool the body to maintain the normal body temperature.
Within 96-120 hrs of the medicine being administered, there is a lowering of the high bilirubin content of the patient and improved sense of appetite subject to the severity of the disease. Geenerai improvement is seen in reduction in nausea, increase in appetite and general feeling of well being. The yellow colour of Urine generally decreses with passage of time after medication, subject to the bilirubin count of the patient. The patient is advised to consume liquids to keep the body and improve urination. The dosage is repeated every 120 hrs till such time the patients' bilirubi content returns to absolutely normal (upto 1 mg%). For patients suffering from hepatitis B, it is noticed that in many cases the Hepatitis B vims is still detectable in the blood despite their Bilirubin cound returning to normal. In order to remove the Hepatitis B vims beyond detectahle range and cure completely, further dosages are given to the patients every 120 hrs till such time the blood test indicates no presence of the Hepatitis B virs, indicatin full recovery. For patients who are tested positive for Hepatitis B and not having above normal bilirubin counts, the effects of urine color, yellow discharge through nose/mouth etc may not be prevalent. The number of dosages to cure Hepatitis B vims depends on the period since initial infection on the patients. It is observed that recently infeted patients get cured with lesser number of dosages and vice versa. In most patients the throat pain which is felt for 24 hrs post administering the medicine, is notable only in the first two times of applications and is much reduced for subsequent ones.
EXAMPLES OF TEST CASES:
a) Case 1:
A 32 year aged female was diagnosed with HBs Ag positive on 18 Dec 2003. Her Total Bilirubin was 16.3 mg/dl and Bilirubin (Direct) was 10.2 mg/dl On 19 Dec 2003. An ultra sound scan revealed that liver is normal in size and echo texture with no focal space occupying lesions in liver and Prtal venous system normal. Gall bladder was only mildly distended with normal wall thickness with Kidney and Pancreas being normal. This person was administered with a strong dose consisting of 3 gm of Ingredient 1 and 2 gm of ingredient 2 in 5 ml of Ingredient 3 and 2ml each of the final solution was administered as nasal drops. Subsequently every 120 hrs (5 days) the patient was given the normal doses. The improvement profile is as follows.
On 09 Jan 2004 Her Bilirubin count reduced drastically to 5.4 mg% and direct Bilirubin
was 2.9 mg%.
On 30 Jan 2004 her total bilirubin was 1.5 mg% and direct Bilirubin was 0.9mg% which vas very close to normal. The HBSAg was still tested positive. The patient was therefore continued on normal dosage very 120hrs.
On 25 March 2004 the patient was tested and found HbsAg NEGATIVE and normal Bilirubin count. The patient has fully recoevred and has since been leading a normal life.
b) Case 2:
A 45 years old male was diagnosed of Viral Hepatitis on 02 Nov 2002 with a Bilirubin total of 5.0mg% and Direct 2.2mg%. The SGPT count was 420U/L
Another test on 07 Nov 02 revealed SGPT as 1450IU/L. On 28 Nov 02 he was diagnosed HGsAgPOSITIVE.
On 09 Dec 02, The bilirubintotal count was 10.4 mg/dl and direct was 9.2 mg/dl. The patient then requested treatment and was administered one strong dose as referredin para above and subsequently normal doses every 120 hrs. The improvement profile is listed below.
On 31 Dec 027 the patient's blood test showed Bilirubin total count 2.2mg/dl and direct Bilirubin 1.2mg/dl.
On 18 Jan 03 the patients blood test revealed a Bilirubin total count of 1.6mg/dl and direct Bilirubin 1.1 mg/dl. The patient was still BGs Ag positive.
On 03 Feb 2003, a Bilirubin total count of 0.8mg/dl and direct Bilirubin 0.6mg/dl was found in his blood test which was in normal limits. The normal dosages of medicine was continued every 120 hrs.
On 24 Feb 2003 HBs Ag ELISA test on the patients blood proved NEGATIVE recording complete recovery and the patient is leading a normal life since then.
c) Case 3:
A 22 years aged fetnal was diagnosed with Viral hepatitis and on blood test her SGPT was 1030 IU/L far above normal limits upto 49IU/L
On 13 Nov 2002, her bilirubin total count was 5.5mg% and direct Bilirubin was 2.2mg% with SGOT 720 IU/L and SGPT 850 IU/L normal being 6-38 IU/L and upto 49 IU/L
These levels increased to Bilirubin total count of 7.9mg% and direct Bilurubin 3.5 mg% when tested on 16 Nov 2004.
Subsequently on 20 Nov 2002 the patient was tested HbsAG(LATEX AGG) POSITIVE with a Bilirubin total count of 15.2mg% and direct Bilirubin 4.6 mg% and SGP value
On 09 Dec 2002 the patient was tested with a Bilirubin total count of 16.6 mg/dl and direct Bilirubin 14.6 mg/dl/
The patient requested treatment and was adminstered with two strong dosages with 120 his apart and normal dosages subsequently eveiy 120 hrs. The improvement is detailed below.
On 31 Dec Bilirubin total count reduced drastically to 3.5mg/dl and direct Bilirubin of 2.9mg/dl was noted.
A blood test on 18 Jan 2003 showed further reduction of Bilirubin levels to 2.6mg/dl with a direct count of 1.5mg/dl. These reduced further normal Bilirubin values of 1.2mg/dl total and direct value of 0.6mg/dl. The dosages still continued due to the patient being HBS Ag POSITIVE.
On 24 March 2003 the blood test (ELISA) on the patient concluded that the patient had fully recovered and tested NEGATIVE for HbsAg.
d) Case 4:
A 25 year old male of normal physique had normal levels of SGPT of 24 IU/L and SGPT 1 7 IU/L with a bilirubin total count of 0.9mg/dl and blood urea of 17 mg/dl which are all in normal Imits. The patients urine test revealed NO ABNORMALITY. However, when tested for a medical examination he was detected HBsAgPOSITIVE. This is a case seen very prevalent wherein the Viral Hepatitis is not yet developed while the HB vims is still active in the body showing no symptoms of jaundice or associated diseases. The patient was treated to 5ml of normal dosage 12 times with 120 hrs in between dosages and he was checked twice for Hepatitis B vims and was found NEGATIVE both the times. The patient continues to lead a normal and healthy life. The patient was tested two years later and still found to be Hepatitis B NEGATIVE.
e) Case 5:
A normal male of 30 years contracted Hepatitis B vims and was tested positive on 3 I Oct 2002. the patient suffered form Jaundice and the initial Bilirubin counts were abormally high to 10 mg/dl. The patient requested treatment and was administered with 10 applications of normal dosages with 120 hours in between. The patient had a normal total hilifubin level of 0.9 mg/dl and had no symptoms of Jaundice. However, the Hbvirus was still POSITIVE. Another three normal doses were given to the patient and the subsequent tests proved NEGATIVE for Hepatitis B vims on 05 March 2003. The patient leads a normal life since then.
0 Case 6:
A femal of 28 years was diagonised with Viral Hepatitis. The blood tests ON 10 Sep 98 reported TC-6250/cumm, DC-P-50%, L-49% and E-1% with SGPT 452 IU/L and Hbs Ag POSITIVE. After seven doses of normal treatment with 120 hrs between each dosages, the patients. SGPT reduced drastically to 159.1 IU/L and displayed improved, good appetite and complete normalacy physically. The patient was still hepatitis B POSITIVE as on 15 Oct 1998. After five more doses with 120 hrs in between the patient recovered completely and was tested Hepatitis B NEGATIVE. She continues to live a normal life till date.
The cases listed aboev are just a few of the hundreds of patients cured of Hepatitis B. These were listed as typical case studies since data regarding their testes etc have been recorded and kept. Every single patient regardless of the age (from 3 yrs to 80 yrs) has responded well to the treatment with no long standing side effects displayed till date. The immediate effects of the drug on the pateints are enumerated at para 2 as above.Cases pertaining to Hepatitis A cure has not been listed as there are thousands of patients treated and cured with a success rate of 100% and already a Process patent to this effect has been sealed fo us. The medicine is therefore highly effective to counter Hepatitis of types A,B,C,D,E. Tests on hepatitis D have not been done on patients due to non availability of well equipped labs and these tests being expensive fro them. Potential of this drug to act as a preventive medicine against Hepatitis B has been verified from the fact the recurrence of Hepatitis in patients treated with this medicine is NIL. It can be safely and surely assumed that Hepatitis D can also be cured by this medicine because Hepatitis D virus, mandatorily requires the presence of Hepatitis vims B in the body to be active. And this medicine can cure Hepatitis B as shown in case studies above.
Patients have been found to respond depending on their immunolgical, metabolical and biological status and same dosages to different people can have different effects in reduction of Bilirubin / SGPT/SGOT, hepatitis Bag levels with regard to time. It has been observed over years that this medicine does not react/interact with any other general type of medication already being taken by the patient for any other disease parallely. Thus, there is no precondition or criteria required to be met by a patient of Hepatitis to avail this treatment except in the following circumstances.
a) The patient is suffering from Typhoid, Malaria, Wheel's Syiidrome parallely with hepatitis B. In such case the other disease may be treated independently and cured first. Hepatitis can be cured subsequently though the bilirubin counts would have risen in this time period.
b) Persons suffering from Chronic ENT related diseases with infection in Throat, Ear and Nose. They may be treated for the same and on its cure they can start this Hepatitis Medication.
c) Personnel with severe brain damage restricting normalacy in swallowing / breathing etc.
d) Personnel suffering from high bilirubin levels due to surgical reasons wherein operation is warranted.
e) A miniscule percentage of people with hereditary liver problems showing high bilirubin levels normally with out any symptoms.
a. Selecting the Luffa Ageypica preferably in its fruit form, drying it.
b. Selecting the Guminam Diminum, preferably in its seed form, drying and
pulverising the same, in the form of fine powder;
c. Thoroughly mixing the said powder form of Luffa Ageypica with the said
powder form of Guminam Diminum in the ratio of 10-35% to 90-65% by
weight or 2-5% to 98-95% by weight;
d. Dissolving the said mixture of step C in a sterilised liquid such as Milk or
water to form a liquid solution / formulation to be used as nasal drops;
e. Packing the said liquid formulation of step D in suitable packing with or
without droper/applicator of the known type for applying the solution
nasal drops in the nose of the patient as and when required;
The milk used is preferably containing low fat contens. The milk may be human milk or animal milk such as cow milk or the like. The mixture of step C may be dissolved in the liquid like human milk just before the application of the medicine.
As an alternative the human milk or the animal milk may be pasturized and mixed with the mixture of step C in the ratio of 55-85% to 45-15% and at the time of application it may be dissolved in a distilled / boiled and cooled water to form the liquid formulation to he applied as a nasal drop at the time of use.
The medicine is very effective in the treatment of all types of viral hepatitis/jaundice, Australia antigen, chronic hisnophilic, cold and the like diseases. A single dose is sufficient in bringing down the bilirubin count of about 3 to 4 to the normal that is 0.8 to 1.2 . In case of severality the medicine is required to be repeated at an interval of 3 to 7 days depending upon the increased count of bilirubin level.
The medicine is very much effective along with the application oil/cow ghee.
The above discription is given just to understand the invention rather than to limit its scope.
The percentage of the hereinbefore described Ayurvedic ingredients/herbs may vary from diseases to diseases and severality and complications of the diseases.
We claim :
1) An ayurvdic medicine / formulation for curing viral hepatatis /jaundice, australia antigen, chronic hisnophilic cold and the like diseases by flushing out of the body excess biluribum and vims comprising extract of dry fibrous fruit of Luffa Aegyptiaca / Luffa Aegyptica / Luffa Cylindrica or Aluffa Acutangula or Luffa Operculata and seeds of Cuminum Cyminum, human breast milk / animal milk / water forming a homogeneous solution.
2) An ayurvedic medicine / formulation for curing viral hepatatis as claimed in claim 1 wherein the said solution is .used as nasal drops for administering to cure the jaundice / viral hepatatis / australia antigen, chronic hisnophilic cold and the like diseases.
3) An ayurvedic medicine / formulation for curing viral hepatatis as claimed in claim 1 or 2 wherein the said nasal drop solution consist of Luffa Aegyptiaca / Luffa Aegyptica / Luffa Cylindrica or Aluffa Acutangula or Luffa Operculata dry fibrous fruit extract, Cuminum Cyminum seed extact and human breast milk / animal milt / water in the ratio of 2 to 3 : 2 : 5 preferably for a normal dose the ratio is 1 : 1 : 2.5.
4) An ayurvedic medicine / formulation for curing viral hepatatis as claimed in claim 1, 2 or 3 wherein 2ml to 5ml of the said nasal drop solution is administered into each nasal of an adult patient.
5) An ayurvedic medicine / formulation for curing viral hepatatis as claimed in claim 4 wherein typically 2 ml of the said nasal drop solution is administered into each nasal of an adult patent as a normal doses.
6) An ayurvedic medicine / formulation for curing viral hepatatis and the like diseases substantially as herein described and explained in the examples.
7) A process of preparing an Ayurvedic Medicine for bringing down bilirubin
count in the body.
(a) Selecting the Luffa Agepica preferably in its fruit form, drying and pulverising the sameinthe form of fine powder;
(b) Selecting the Guminam Diminum, preferably intos seed form, drying and pulverising the same, in the form of fine powder;
(c) Thoroughly mixing the said powder form of Luffa Agypica with the said powder form of Guminam Diminum in the ratio of 10-35% to 90-65% by weight or 2-5% to 98-95% by weight.
8) A process of preparing an Ayurvedic Medicine for curing Viral Hepatitis / Jaundice and the like dieseases as claimed in claim 1 wherein the said mixture of step C is dissolved in a sterilised liquid such as milk or water to form a liquid solution/formulation to be used as nasal drops.
9) A process of preparing an Ayurvedic medicine for curing Viral Hepatitis/jaundice and the like diseases as claimed in claim 2 wherein the said mixture of step C is dissolved in the said stipulated liquid to form a liquid solution to be used as a nasal drop at the time of application of the medicine.
10) A process of preparing an Ayurvedic Medicine for curing Viral Hepatitis / Jaundice and the like diseases wherein the said mixture of step C is dissolved in the said sterilised liquid to form a ready made solution/formulation to be used as nasal drops as and when required.
1 1) A process of preparing an Ayurvedic medicine for curing Viral Hepatitis / Jaundice and the like diseases as claimed in Claim 4 wherein the said liquid solution/formulation is packed in a suitable packing with or without a draper / applicator for applying the nasal drops in the nose of the patient as and when required.
12) A process of preparing an Ayurvedic medicine for curing Viral Hepatitis/Jaundice
and the like diseases, as claimed in anyof the preceeding claims 2 to 5 wherein the
said milk used inpreferably containing low fat contents.
13) A process of preparing an Ayurvedic medicine for curing Viral Hepatitis/Jaundice
and the like diseases, as claimed in claim 6 wherein the said milk is human milk
or animal milk like cow milk.
14) A process of preparing an Ayurvedic medicine for curing Viral Hepatitis/Jaundice
and the like diseases, substantially as herein described.
726-CHE-2005 AMANDED CLAIMS 22-01-2010.pdf
726-CHE-2005 AMANDED PAGES OF SPECIFICATION 22-01-2010.pdf
726-CHE-2005 CORRESPONDENCE OTHERS 22-01-2010.pdf
726-che-2005 abstract 27-08-2009.pdf
726-che-2005 claims 27-08-2009.pdf
726-che-2005 description (complete) 27-08-2009.pdf
726-CHE-2005 EXAMINATION REPORT REPLY RECIEVED 27-08-2009.pdf
726-che-2005 form-1 27-08-2009.pdf
726-CHE-2005 FORM-2 27-08-2009.pdf
|Indian Patent Application Number||726/CHE/2005|
|PG Journal Number||36/2010|
|Date of Filing||15-Jun-2005|
|Name of Patentee||THOMAS K JACOB|
|Applicant Address||KONDOOPARAMPIL HOUSE, KALPETTA, WYNAD, KERALA|
|PCT International Classification Number||A61K 35/78|
|PCT International Application Number||N/A|
|PCT International Filing date|